Clinical trials: Chemotherapy Induced Neutropenia
Fever, Neutropenia
Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting
The purpose of this study is to determine whether, in children with cancer presenting with fever in severe chemotherapy-induced neutropenia at low risk for medical complications, oral antibiotics in an outpatient setting after an…
- Conditions
- Fever, Neutropenia, Cancer
- Trial name
- NCT00107081
- Testing
- ciprofloxacin and amoxicillin, Outpatient management, i.v. antibiotics
- Where
- 12 sites in Germany, Netherlands and 1 more
- Volunteers
- 70 people
- Sponsor
- Swiss Pediatric Oncology Group
Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer patients.
- Conditions
- Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced, Epithelial Ovarian Cancer, Colony Stimulating Factors Adverse Reaction
- Trial name
- NCT04101760
- Testing
- Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lei Li
Non-small Cell Lung Cancer
Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer
TLK199.2102 was a multicenter Phase 2 randomized study to determine the effect of Telintra treatment on chemotherapy induced neutropenia (CIN) in patients with non small cell lung cancer receiving first-line therapy with…
- Trial name
- NCT00701870
- Testing
- ezatiostat hydrochloride (Telintra®)
- Where
- 24 sites in United States
- Volunteers
- 1 people
- Sponsor
- Telik
Chemotherapy-induced Neutropenia
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus…
- Trial name
- NCT03294577
- Testing
- Pegfilgrastim, Plinabulin, Docetaxel, doxorubicin, and cyclophosphamide (TAC)
- Where
- 20 sites in China, Ukraine
- Volunteers
- 221 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Patient Preference, Febrile Neutropenia, Drug-Induced
Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim
Febrile neutropenia (NF) is a common serious complication of cancer chemotherapy. Outpatient management of chemotherapy treatments is made essential by the volume of patients treated, respect for their quality of life and the…
- Conditions
- Patient Preference, Febrile Neutropenia, Drug-Induced, Patient Satisfaction
- Trial name
- PELGRAZ (NCT05910164)
- Testing
- PELGRAZ prefilled syringe or PELGRAZ prefilled pen
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut Rafael
Chemotherapy-Induced Febrile Neutropenia
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
- Trial name
- NCT06616571
- Testing
- QL0605(PEG-rhG-CSF)
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia…
- Trial name
- NCT02953340
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 74 sites in United States, Canada and 4 more
- Volunteers
- 237 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Chemotherapy-induced Neutropenia
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
The present study was an observational, multicenter, non-interventional, single arm, open label, PMS study conducted in Iran. The primary objective of this study was safety assessment, including the rate of AEs.
- Trial name
- NCT04460079
- Testing
- Peg-filgrastim
- Volunteers
- 654 people
- Sponsor
- Cinnagen
Chemotherapy-Induced Febrile Neutropenia
Safety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile Neutropenia
Febrile neutropenia (FN) continues to be the infectious complication that most commonly requires hospitalization in pediatric cancer patients undergoing chemotherapy.
- Trial name
- NCT04000711
- Testing
- Outpatient oral treatment., Inpatient intravenous treatment.
- Volunteers
- 117 people
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
Chemotherapy-induced Neutropenia, Breast Cancer
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
- Trial name
- PROTECT2 (NCT01516736)
- Testing
- LA-EP2006, Neulasta®
- Where
- 53 sites in United States, Argentina and 6 more
- Volunteers
- 308 people
- Sponsor
- Sandoz
Septic Shock, Nonchemotherapy Drug-induced Neutropenia
Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia
Septic shock remains a significant clinical problem associated with high rates of mortality among neutropenic patient despite antimicrobial therapy and supportive care.
- Conditions
- Septic Shock, Nonchemotherapy Drug-induced Neutropenia, Neutropenia After Chemotherapy in Oncohematological Patients, Neutropenia in Patients With Aplastic Anemia
- Trial name
- NCT01849237
- Testing
- Mesenchymal stromal cells, Standard therapy of septic shock
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- National Research Center for Hematology, Russia
Neoplasms (no Otherwise Specified)
A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen
Primary Objective: To evaluate the incidence and severity of neutropenia in patients being treated for solid tumours with a Taxotere® based regimen when Granocyte® 34 is being used as a primary prophylaxis for…
- Trial name
- Grano-Tax (NCT01107756)
- Testing
- LENOGRASTIM (GRANOGYTE 34)
- Where
- 25 sites in South Africa
- Volunteers
- 403 people
- Sponsor
- Sanofi
Chemotherapy-induced Neutropenia
Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein
The purpose of this study is to evaluate the dosages of recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein by injection for preventing neutrophilic granulocytopenia among chemotherapy patients.
- Trial name
- NCT02465801
- Testing
- HSA-GCSF 1.2 mg, HSA-GCSF 1.5 mg, GCSF
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Myelosuppression Adult, Chemotherapeutic Toxicity
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
The purpose of this expanded access protocol is to provide access to trilaciclib for chemotherapy-induced myelosuppression in patients receiving chemotherapy as a treatment for small cell lung cancer (SCLC).
- Conditions
- Myelosuppression Adult, Chemotherapeutic Toxicity, Small Cell Lung Cancer
- Trial name
- NCT04504513
- Testing
- Trilaciclib
- Sponsor
- G1 Therapeutics, Inc.
Stage III Colorectal Cancer, Neutropenia
A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.
This is a randomized, double-blind, placebo-controlled multi-center phaseⅢstudy to evaluate efficacy and safety of oxaliplatin-based chemotherapy plus MB-6(320 mg/capsule, 6 capsules tid) in patients with stage 3 colorectal…
- Trial name
- MB-6 (NCT02135887)
- Testing
- MB-6
- Where
- Taiwan
- Volunteers
- 184 people
- Sponsor
- Microbio Co Ltd
Chemotherapy-induced Febrile Neutropenia
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
This is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy.
- Trial name
- NCT01813721
- Where
- 90 sites in Australia, Austria and 9 more
- Volunteers
- 1,007 people
- Sponsor
- Amgen
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00003407
- Testing
- amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Rush University Medical Center
Chemotherapy Induced Neutropenia, Pediatric Solid Tumor
Pegteograstim in Children With Solid Tumors
To evaluate the efficacy and safety of pegteograstim on chemotherapy-induced neutropenia in children with solid tumors
- Trial name
- NCT02787876
- Testing
- Pegteograstim
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Samsung Medical Center
Leukemia, Leukemia, Myeloid
Breath Analysis for the Detection of Invasive Fungal Infections
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Lymphoblastic, Neutropenia
- Trial name
- REDEFINE (NCT06537726)
- Testing
- Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
- Where
- Switzerland
- Volunteers
- 130 people
- Sponsor
- University of Zurich
Breast Cancer
The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia
The purpose of this study is to evaluate the safety and efficacy of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia
- Trial name
- NCT02761460
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 338 people
- Sponsor
- wang shusen